Use of Intranasal Oxytocin During Detoxification of Crack Cocaine

Cocaine-Related Disorders Clinical Trial

Official title:

Randomized, Double-Blind, Placebo Controlled Study of Intranasal Oxytocin During Detoxification of Crack Cocaine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04306354
• Other study ID #: U1111-1188-6555
• Secondary ID: U1111-1188-65553
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 15, 2018
• Est. completion date: May 31, 2020

Study information

• Verified date: March 2020
• Source: Pontificia Universidade Católica do Rio Grande do Sul
• Contact: Rodrigo Grassi-Oliveira, MD, PhD
• Phone: +555133203633
• Email: rodrigo.grassi[@]pucrs.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized treatment control trial, double-blind, parallel, with two arms including ninety-six hospitalized women between 18 and 52 years. Those who agree to participate in the study and meet the eligibility criteria will be randomly allocated to one of the following experimental conditions:

• Conventional oxytocin treatment (T + OC): 32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.

• Conventional treatment with placebo administration (T + PBO): 32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.

• Conventional treatment (T): 32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.

Outcomes: Withdrawal symptoms, Anxiety symptoms and Depressive symptoms

Description:

Design: Randomized treatment control trial, double-blind, parallel, with two arms.

Sample: Ninety-six hospitalized women between 18 and 52 years will participate in this study. Those who agree to participate in the study and meet the eligibility criteria will be randomly allocated to one of the following experimental conditions:

• Conventional oxytocin treatment (T + OC): 32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.

• Conventional treatment with placebo administration (T + PBO): 32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.

• Conventional treatment (T): 32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.

Inclusion Criteria:

• Volunteers (no payment to be enroll in the research according with Brazilian legislation)

• Age 18-52 years

• Primary diagnosis of cocaine crack dependence according to DSM-5

• Sex feminine

• Participants must be abstinent at least 7 days prior the study intervention

• Participants must consent to be randomly allocated to experimental conditions

Exclusion Criteria:

• Pregnancy

• Puerperium

• Breastfeeding

• Menopause

• Currently using hormone therapy

• Total hysterectomy

• Diagnosis or suspicion of autoimmune or neurological diseases and / or syndromes (stroke, Parkinson and Alzheimer's)

• Diagnosis or suspected current decompensated and / or severe endocrine, cardiovascular, pulmonary, renal, gastrointestinal disorders

• Moderate or severe psychotic syndrome

• Obesity Level III

• Intellectual impairment (IQ <70)

• Corticosteroid therapy, glucocorticoid or any exogenous steroid therapy

• Infectious condition or acute febrile syndrome

• Significant nasal congestion

• Type III nasal septum deviation (cases considered severe with deviated septum in which breathing is impaired)

• Mucosal lesions

• History of head trauma moderate or severe (Glasgow <12)

• HIV +

Primary Outcome Measure:

1. Withdrawal symptoms Change from baseline withdrawal symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by Cocaine Selective Severity Assessment (CSSA, minimum and maximum scores: 0 - 112). After treatment, the oxytocin-treated group is expected to have significantly lower withdrawal scores (better outcome) than the other groups (30%).

2. Anxiety symptoms Change from baseline anxiety symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by the Patient-Reported Outcomes Measurement Information System Short Form scale (PROMIS, minimum and maximum raw scores: 8 - 40). After treatment, the oxytocin-treated group is expected to show lower anxiety scores (better outcome) compared to the other groups (30%).

3. Depression symptoms Change from baseline depressive symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by the Quick Inventory of Depressive Symptomatology Self-Report scale (QIDS-SR, minimum and maximum scores: 0 - 27). After treatment, the oxytocin-treated group is expected to show lower depressive scores (better outcome) compared to the other groups (30%).

Secondary Outcome Measures:

1. Neuroleptic Dose Change Dose change of neuroleptic medications used during hospitalization for agitation or irritability (expected 25% lower).

2. Adherence of outpatient treatment Rate of adherence of outpatient treatment six months after discharge (expected to be 20% higher) assessed by reviewing the medical records of each patient within the outpatient program. If patient would be enrolled in the outpatient program after six months from detoxification she will be considered adhered to the program (higher rates means better outcome).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: May 31, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 52 Years

Eligibility

Inclusion Criteria:

• Volunteers (no payment to be enroll in the research according with Brazilian legislation)

• Age 18-52 years

• Primary diagnosis of cocaine crack dependence according to DSM-5

• Sex feminine

• Participants must be abstinent at least 7 days prior the study intervention

• Participants must consent to be randomly allocated to experimental conditions

Exclusion Criteria:

• Pregnancy

• Puerperium

• Breastfeeding

• Menopause

• Currently using hormone therapy

• Total hysterectomy

• Diagnosis or suspicion of autoimmune or neurological diseases and / or syndromes (stroke, Parkinson and Alzheimer's)

• Diagnosis or suspected current decompensated and / or severe endocrine, cardiovascular, pulmonary, renal, gastrointestinal disorders

• Moderate or severe psychotic syndrome

• Obesity Level III

• Intellectual impairment (IQ <70)

• Corticosteroid therapy, glucocorticoid or any exogenous steroid therapy

• Infectious condition or acute febrile syndrome

• Significant nasal congestion

• Type III nasal septum deviation (cases considered severe with deviated septum in which breathing is impaired)

• Mucosal lesions

• History of head trauma moderate or severe (Glasgow <12)

• HIV +

Related Conditions & MeSH terms

• Cocaine Smoking
• Cocaine Withdrawal
• Cocaine-Related Disorders

Intervention

Drug:
• Oxytocin nasal spray
Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
• placebo nasal spray
Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.

Locations

Country	Name	City	State
Brazil	Hospital Santa Ana	Porto Alegre	RS

Sponsors (3)

Lead Sponsor	Collaborator
Pontificia Universidade Católica do Rio Grande do Sul	Conselho Nacional de Desenvolvimento Científico e Tecnológico, Secretaria Nacional de Políticas sobre Drogas (SENAD)

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Withdrawal symptoms	Change from baseline withdrawal symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by Cocaine Selective Severity Assessment (CSSA, minimum and maximum scores: 0 - 112). After treatment, the oxytocin-treated group is expected to have significantly lower withdrawal scores (better outcome) than the other groups (30%).	Change from baseline (first week after hospital admission) at the end of detoxification treatment (21 days).
Primary	Anxiety symptoms	Change from baseline anxiety symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by the Patient-Reported Outcomes Measurement Information System Short Form scale (PROMIS, minimum and maximum raw scores: 8 - 40). After treatment, the oxytocin-treated group is expected to show lower anxiety scores (better outcome) compared to the other groups (30%).	Change from baseline (first week after hospital admission) at the end of detoxification treatment (21 days).
Primary	Depression symptoms	Change from baseline depressive symptoms (hospital admission) at the end of detoxification treatment (21 days) assessed by the Quick Inventory of Depressive Symptomatology Self-Report scale (QIDS-SR, minimum and maximum scores: 0 - 27). After treatment, the oxytocin-treated group is expected to show lower depressive scores (better outcome) compared to the other groups (30%).	Change from baseline (first week after hospital admission) at the end of detoxification treatment (21 days).
Secondary	Neuroleptic Dose Change	Dose change of neuroleptic medications used during hospitalization for agitation or irritability (expected 25% lower).	Change from baseline (first week after hospital admission) at the end of detoxification treatment (21 days)
Secondary	Adherence of outpatient treatment	Rate of adherence of outpatient treatment six months after discharge (expected to be 20% higher) assessed by reviewing the medical records of each patient within the outpatient program. If patient would be enrolled in the outpatient program after six months from detoxification she will be considered adhered to the program (higher rates means better outcome).	six months after hospital discharge